Integrated transcriptomic and immune analysis reveals distinct mitochondrial and immune signature in COVID-19 ARDS requiring invasive mechanical ventilation - Scorecard - MDSpire

Integrated transcriptomic and immune analysis reveals distinct mitochondrial and immune signature in COVID-19 ARDS requiring invasive mechanical ventilation

  • By

  • Deepa B. Gotur

  • Diksha M. Gowda

  • Decha Pinkaew

  • Aijun Zhang

  • Spencer Hankins

  • Shaefali Rodgers

  • Yitian Xu

  • Mohi U. Syed

  • Tejaswini Reddy

  • Hong Zhao

  • Junjun Zheng

  • Rodney J. Folz

  • Eleftherios Mylonakis

  • Dale J. Hamilton

  • July 8, 2026

  • 0 min

Share

Clinical Scorecard: Comprehensive Transcriptomic and Immune Profiling Identifies Unique Mitochondrial and Immune Signatures in COVID-19 Related ARDS Necessitating Invasive Mechanical Ventilation

At a Glance

CategoryDetail
ConditionCOVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
Key MechanismsMitochondrial dysfunction, cytokine storm, immune exhaustion
Target PopulationPatients with severe COVID-19 requiring invasive mechanical ventilation
Care SettingHospitalized patients in intensive care units

Key Highlights

  • IMV patients had longer hospital and ICU stays compared to non-IMV patients.
  • 28-day mortality was significantly higher in the IMV group (45.5% vs. 12.0%).
  • Distinct transcriptomic profiles were identified in IMV patients, including downregulation of mitochondrial gene MTARC2.
  • Elevated plasma IL-6, IL-8, and IL-10 levels were observed in IMV patients, with IL-10 showing strong predictive value.
  • Higher percentage of CD57− NK cells was found at baseline in the non-IMV group.

Guideline-Based Recommendations

Diagnosis

  • Utilize transcriptomic and immune profiling to distinguish between IMV and non-IMV patients.

Management

  • Monitor cytokine levels, particularly IL-10, as potential prognostic biomarkers.

Monitoring & Follow-up

  • Assess hospital and ICU stay duration and 28-day mortality rates in patients with ARDS.

Risks

  • Patients requiring IMV are at higher risk for prolonged hospitalization and increased mortality.

Patient & Prescribing Data

Adults (≥18 years) with PCR-confirmed SARS-CoV-2 infection requiring supplemental oxygen.

Identification of biomarkers may guide treatment decisions and prognostication.

Clinical Best Practices

  • Conduct comprehensive immune profiling in patients with severe COVID-19 ARDS.
  • Evaluate mitochondrial function as a potential therapeutic target.

Related Resources & Content

    Original Source(s)

    Integrated transcriptomic and immune analysis reveals distinct mitochondrial and immune signature in COVID-19 ARDS requiring invasive mechanical ventilation

    • by Deepa B. Gotur, Diksha M. Gowda, Decha Pinkaew, Aijun Zhang, Spencer Hankins, Shaefali Rodgers, Yitian Xu, Mohi U. Syed, Tejaswini Reddy, Hong Zhao, Junjun Zheng, Rodney J. Folz, Eleftherios Mylonakis, Dale J. Hamilton

    • July 8, 2026

    Related Content

    Makary Resigns as FDA Commissioner Following Policy Disputes

    Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

    Symptom burden, lung function, exercise tolerance and inflammation in patients post COVID-19: results from the prospective COVID-19 Chronic Morbidity (CCHROMO) study

    Recent COVID-19 Shot Linked to Less Spread

    Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.